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Background: To directly compare traditional lipid ratios (total cholesterol [TC]/high density lipoprotein cholesterol
[HDL-C], non-HDL-C/HDL-C, low density lipoprotein cholesterol [LDL-C]/HDL-C, and triglycerides [TG]/HDL-C),
apolipoprotein B (apoB)/apolipoprotein A-I (apoA-I) ratio, visceral adiposity index (VAI), lipid accumulation product (LAP),
and the product of TG and fasting glucose (TyG) for strength and independence as risk factors for insulin resistance (IR).
Methods: We conducted a cross-sectional analysis of 7629 Chinese adults using data from the China Health and Nutrition
Survey 2009.
Results: For all lipid ratios (traditional lipid ratios and apoB/apoA-I), among both sexes, TG/HDL-C explained the most
additional percentage of variation in HOMA-IR (2.9% in men, and 2.3% in women); for all variables of interest, the variability
in HOMA-IR explained by VAI and TG/HDL-C were comparable; TyG had the most significant association with HOMA-IR,
which explained 9.1% for men and 7.8% for women of the variability in HOMA-IR. Logistic regression analysis showed the
similar patterns. Receiver operating characteristic (ROC) curve analysis showed that, among both sexes, TG/HDL-C was a
better discriminator of IR than apoB/apoA-I; the area under the ROC curve (AUC) for VAI (0.695 in men and 0.682 in women)
was greater than that for TG/HDL-C (AUC 0.665 in men and 0.664 in women); TyG presented the greatest value of AUC
(0.709 in men and 0.711 in women).
Conclusion: The apoB/apoA-I performs no better than any of the traditional lipid ratios in correlating with IR. The TG/
HDL-C, VAI and TyG are better markers for early identification of IR individuals.
Keywords: Insulin resistance, Apolipoprotein B, Apolipoprotein A-I, Visceral adiposity index, Lipid accumulation product,
TyG indexBackground
Cardiovascular disease (CVD) is now the leading cause of
morbidity and mortality worldwide. The new epidemic of
diabetes is fuelling an alarming increase in premature CVD
incidence. Insulin resistance (IR) and the consequence of
compensatory hyperinsulinemia are fundamentally patho-
genetic factors for a set of metabolic abnormalities [1],
which contribute to the development of diabetes and CVD.
Thus, detection and treatment of IR before the manifest-
ation of clinical disease are of paramount importance.
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unless otherwise stated.standard test for measurement of IR, it is impractical in
clinical settings due to practical, ethical and economic rea-
sons. Therefore, markers of IR which are simple and easy
to implement are urgently needed. Dyslipidemia is a major
risk factor for CVD. There is evidence suggesting that trad-
itional lipid ratios, such as total cholesterol (TC)⁄ high dens-
ity lipoprotein cholesterol (HDL-C), non-HDL-C/HDL-C,
and triglycerides (TG)/HDL-C, which take account of
the proportion between the pro-atherogenic and anti-
antherogenic fractions, are more effective than single mea-
sures of lipids in detecting IR [2]. A plethora of studies
have shown that apolipoprotein B (apoB)/apolipoprotein
A1 (apoA-I) (in which apo B means apo B100) ratio is su-
perior to traditional lipids in CVD prediction [3-5]. More-
over, one study indicates that apoB/apoA-I is significantlyThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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recommendation that apoB and apoA-I should be mea-
sured in routine clinical care [7]. It is uncertain, however,
whether the apoB/apoA-I ratio is superior to traditional
lipid ratios in detecting IR. Though head-to head compari-
sons between apoB/apoA-I and traditional lipid ratios have
been conducted to evaluate whether apoB/apoA-I could
be used instead of traditional lipid ratios for CVD risk [8],
direct comparisons between these measurements to iden-
tify IR are limited.
On the other hand, emerging evidence indicates that
visceral adiposity is associated with IR [9,10]. The visceral
adiposity index (VAI), a mathematical model that uses both
anthropometric (body mass index [BMI] and waist circum-
ference [WC]) and metabolic (TG and HDL-C) parameters,
and lipid accumulation product (LAP), a mathematical
model that based on a combination of TG and WC, are
sensitive markers of visceral obesity [11,12], and have
the ability to identify IR. Since both the VAI and LAP
incorporates TG along with indicators of adiposity (WC),
they might be superior markers of IR compared with lipid
ratios, as regional fat distribution can modulate cardio-
metabolic risk [9,13]. It has also been suggested that the
product of TG and fasting glucose (TyG) has high sensi-
tivity for recognizing IR [14,15]. Since TyG incorporates
TG along with fasting plasma glucose (FPG), superiority
of TyG in identifying IR might be achieved as both TG
and FPG are well validated for their roles in IR [16,17].
To the best of our knowledge, limited data are available
regarding direct comparisons between the variables men-
tioned above in identifying IR.
Hence, the aims of this study were to: 1) evaluate the
performance of a range of lipids and apolipoproteins, as
well as relevant ratios in identifying IR; 2) directly compare
the traditional lipid ratios, apoB/apoA-I ratio, VAI, LAP,




We used data from the China Health and Nutrition Survey
(CHNS) for our analysis. The CHNS is the only large-scale
longitudinal, household-based survey in China. Full details
of the study have been described elsewhere [18]. Briefly,
the CHNS rounds were conducted in 1989, 1991, 1993,
1997, 2000, 2004, 2006, and 2009. For each round, a strati-
fied multistage, random cluster process was employed
to draw study sample from each of the nine provinces
(Liaoning, Heilongjiang, Jiangsu, Shandong, Henan, Hubei,
Hunan, Guangxi, and Guizhou), covering approximately
56% of China’s population, that vary significantly in terms
of geography, economic development, and health status.
Each participant provided a written informed consent
and the study was approved by the institutional reviewcommittees of the University of North Carolina at Chapel
Hill, the National Institute of Nutrition and Food Safety,
Chinese Center for Disease Control and Prevention, and
the China-Japan Friendship Hospital, Ministry of Health.
Since fasting blood samples were initially collected in
2009, this study examined data from CHNS 2009. All
participants were asked to complete a structured ques-
tionnaire which provided information on educational attain-
ment, cigarette smoking and alcohol consumption habits,
histories of current and previous illness, and medical
treatment. A total of 10,038 adult respondents were sur-
veyed at the 2009 exam, 1,423 did not give blood, 402 were
not fasting before blood collection, and 62 were pregnant,
resulting in a total of 8,151 individuals with fasting blood
samples. Exclusion criteria included a self-reported diabetes
diagnosis or diabetes medication use, chronic kidney disease
(estimated glomerular filtration rate <15 ml/min per
1.73 m2), and extreme BMI (≥40 kg/m2), TG (>500 mg/dl)
or HDL-C (>100 mg/dl) values. The remaining 7629
participants with anthropometry and clinical examination
information were included in current analysis.
Measurements
Weight, height, WC and blood pressure (BP) were mea-
sured following standardized protocols from the World
Health Organization. Weight was measured with partic-
ipants wearing light clothing on a calibrated beam scale
and height was measured without shoes using a port-
able SECA stadiometer. BMI was calculated as weight
(in kilograms) divided by the square of height (in meters).
WC was measured with an inelastic tape at a midpoint be-
tween the bottom of the rib cage and the top of the iliac
crest at the end of exhalation. Seated systolic/diastolic
BP was measured by trained technicians in triplicate
after a 10-min rest, using mercury manometers. The three
readings were averaged.
Biochemical measurements
Blood was collected after an at least 8-hour overnight fast.
All samples were analyzed in a national central lab in
Beijing, with strict quality control. FPG was measured
by the GOD-PAP method (Randox Laboratories Ltd,
UK]. All lipids (TC, TG, low density lipoprotein choles-
terol [LDL-C], and HDL-C) were directly measured with
Hitachi 7600 automated analyzer (Hitachi Inc., Tokyo,
Japan). TC, LDL-C, and HDL-C were measured enzymati-
cally (Kyowa, Japan). Non-HDL-C was calculated as TC
minus HDL-C. TG was measured by GPO-PAP method
(Kyowa, Japan). ApoA-I and apoB were measured by
immunoturbidimetric method (Randox Laboratories Ltd,
UK). Hypersensitive C-reactive protein (hs-CRP) was de-
termined by immunoturbidimetric method (Denka Seiken,
Japan reagents). Fasting insulin concentration was mea-
sured using the radioimmunology assay (Gamma counter
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of insulin resistance (HOMA-IR) was calculated by the
formula: HOMA-IR = fasting insulin (micro-international
units per milliliter) × FPG (millimoles per liter)/22.5.
LAP, VAI, and TyG were calculated using the published
formula. LAP [12]: Men: [WC (cm) – 65] × [TG (mmol/l)];
Women: [WC (cm) – 58] × [TG (mmol/l)]. To avoid hav-
ing nonpositive values for LAP, we reassigned any WC
values for men/women that were less than 65/58 cm to
66.0/59.0 cm. VAI [11]: Men: [WC/39.68 + (1.88 × BMI)] ×
(TG/1.03) × (1.31/HDL); Women: [WC/36.58 + (1.89 ×
BMI)] × (TG/0.81) × (1.52/HDL), where both TG and HDL
levels are expressed in mmol/l. The TyG index [14,15]: Ln
[TG (mg/dl) × FPG (mg/dl)/2].
Definitions
According to the International Diabetes Federation rec-
ommendations for Asians [19], central obesity is defined
as WC ≥90 cm for men and ≥80 cm for women.
Quartiles of the HOMA-IR were calculated separately
for men and women with FPG <126 mg/dl. IR was de-
fined as having HOMA-IR in the upper quartile of the
HOMA index.
The Framingham risk score (FRS) was calculated ac-
cording to the National Cholesterol Education Program-
Adult Treatment Panel III algorithm [20]. According to
FRS, individuals were categorized into 3 risk groups (low
[<10%], intermediate [10–20%], and high [≥20%]).
Statistical analysis
All statistical analyses were conducted using SPSS software
(version 12.0 for windows; SPSS, Chicago, IL, USA). Con-
tinuous variables were expressed as medians and interquar-
tile ranges (IQR) due to their skewed distribution and were
compared with Mann-Whitney U test between participants
with and without IR. Categorical variables were presented
as percentages and were compared with a Chi-square test.
Variables of interest were TC, TG, LDL-C, HDL-C, apoB,
apoA-I, TC/HDL-C, TG/HDL-C, LDL-C/HDL-C, non-
HDL-C/HDL-C, apoB/apoA-I, LAP, VAI, and TyG. Before
conducting the linear regression analyses, all these vari-
ables except TyG were log-transformed (natural logarithm)
to approximate normal distributions. Multiple linear re-
gression analysis with log HOMA-IR as the dependent
variable was used to assess associations of these log-
transformed variables as well as TyG with HOMA-IR.
The predictive values of each variable were judged by com-
paring the proportion of the total variation that each of the
indexes could explain, that is, the R2 for the entire regres-
sion model minus the R2 for a base model that excluded
each of the indexes. For each index, we divided them into
increasing sex-specific quartile values and used logistic
regression analysis to calculate odds ratios (ORs) and
95% confidence intervals (CIs) for IR comparing thosein quartiles 2 through 4 with those in quartile 1. Three
models were fitted. Model 1 was adjusted for age, socioeco-
nomic status (rural/urban settings, region, and education
level), smoking status, alcohol use, BMI, systolic BP, uric
acid, and hs-CRP. Model 2 was additionally adjusted for
WC. Model 3 was adjusted for BMI, socioeconomic
status, alcohol use, and FRS. A receiver operating char-
acteristic (ROC) curve analysis was performed for each
measure to compare the abilities of these measures to
correctly discriminate IR. The overall diagnostic accuracy
was quantified using the area under the ROC curve
(AUC). Significance was accepted at a two-tailed P <0.05.
Results
Insulin resistant individuals were more likely than insu-
lin sensitive counterparts to be older. BMI, WC, systolic
and diastolic BP, TC, TG, LDL-C, non-HDL-C, apoB, TC/
HDL-C, TG/HDL-C, LDL-C/HDL-C, non-HDL-C/HDL-C,
apoB/apoA-I, LAP, VAI, TyG, FPG, HOMA-IR, uric acid,
and hs-CRP were significantly higher, whereas HDL-C and
apoA-I were lower in insulin resistant individuals than in
insulin sensitive counterparts (Table 1). There were signifi-
cant differences in lipid and apolipoprotein profiles between
men and women; therefore all following analyses were
stratified by sex.
In both sexes, after controlling for potential intermedi-
ate variables, each lipid ratio, and visceral adiposity indi-
cator, as well as TyG considered one-at-a-time made a
significant incremental additive contribution to the pre-
diction of HOMA-IR (all P <0.05). The models with lipid
ratios were consistently superior to those with the single
variables used alone for predicting HOMA-IR (Table 2).
For all lipid ratios (TC/HDL-C, TG/HDL-C, LDL-C/HDL-
C, non-HDL-C/HDL-C, and apoB/apoA-I), the additional
percentage of variation in HOMA-IR explained by each
measure ranged from 1 to 2.9% (model 1) in men, and 0.4
to 2.3% (model 1) in women, with log TG/HDL-C being
the strongest predictor in both sexes; log apoB/apoA-I
was the lipid ratio that had the least association with
HOMA-IR and accounted for 1% for men and 0.4% for
women (model 1) of the variability in HOMA-IR. For
all variables of interest, among both sexes, TyG had the
most significant association with HOMA-IR, which ex-
plained 9.1% for men and 7.8% for women (model 1) of
the variability in HOMA-IR; the variability in HOMA-IR
explained by log VAI and log TG/HDL-C was comparable.
Results were replicated in models 2 and 3.
The direct comparative ORs and 95% CIs for those in
the top quartiles of each variable were presented in Table 3.
For both sexes, after adjustment for age, socioeconomic
status, smoking status, alcohol use, BMI, systolic BP, uric
acid, and hs-CRP (model 1), TG, apoB, non-HDL-C,
HDL-C, each of the lipid ratios, VAI, LAP and TyG were
strongly associated with IR (P <0.001), whereas TC, LDL-
Table 1 Characteristics of the study participants according to gender or presence of insulin resistance (IR)
Men Women P (Men vs women) Non-IR IR p (IR vs non-IR)
n 3619 4010 4829 2800
Age, year 50.6 (39.3-60.7) 51.0 (40.3-60.6) 0.298 50.2 (39.3-59.9) 51.8 (40.7-62.1) <0.001
Male (%) … … … 48.0 46.5 0.1949
Smoking (%) 56.0 3.6 <0.001 29.8 26.1 0.001
Drinking (%) 26.6 2.0 <0.001 14.5 12.3 0.007
Body mass index, kg/m2 23.1 (20.9-25.4) 23.1 (21.0-25.6) 0.328 22.4 (20.4-24.6) 24.4 (22.0-27.0) <0.001
Waist circumference, cm 84.0 (77.0-91.0) 80.0 (74.0-88.0) <0.001 80.0 (74.0-87.0) 86.0 (79.0-93.0) <0.001
Systolic blood pressure, mmHg 121.7 (114.0-135.3) 120.0 (110.0-132.7) <0.001 120.0 (110.0-130.7) 123.3 (116.7-139.3) <0.001
Diastolic blood pressure, mmHg 80.7 (75.7-89.3) 80.0 (70.7-85.3) <0.001 80.0 (70.7-86.0) 80.7 (76.7-89.3) <0.001
Total cholesterol (TC),
mmol/l
4.7 (4.2-5.4) 4.8 (4.2-5.6) <0.001 4.7 (4.1-5.4) 4.9 (4.3-5.6) <0.001
Triglycerides (TG) , mmol/l 1.3 (0.9-1.9) 1.2 (0.9-1.8) <0.001 1.1 (0.8-1.6) 1.5 (1.1-2.3) <0.001
High density lipoprotein cholesterol (HDL-C), mmol/l 1.3 (1.1-1.6) 1.4 (1.2-1.7) <0.001 1.4 (1.2-1.7) 1.3 (1.1-1.5) <0.001
Non- HDL-C, mmol/l 3.3 (2.8-4.0) 3.3 (2.7-4.1) 0.936 3.2 (2.6-3.9) 3.6 (3.0-4.3) <0.001
Low density lipoprotein
cholesterol (LDL-C), mmol/l
2.9 (2.3-3.5) 3.0 (2.4-3.6) <0.001 2.9 (2.3-3.5) 3.0 (2.4-3.7) <0.001
TC/HDL-C 3.5 (2.9-4.4) 3.3 (2.8-4.1) <0.001 3.2 (2.7-3.9) 3.8 (3.1-4.6) <0.001
TG/HDL-C 0.9 (0.6-1.6) 0.8 (0.5-1.3) <0.001 0.8 (0.5-1.2) 1.2 (0.7-1.9) <0.001
LDL-C/HDL-C 2.2 (1.6-2.8) 2.1 (1.6-2.6) <0.001 2.0 (1.5-2.5) 2.3 (1.8-2.9) <0.001
Non-HDL-C/HDL-C 2.5 (1.9-3.4) 2.3 (1.8-3.1) <0.001 2.2 (1.7-2.9) 2.8 (2.1-3.6) <0.001
Apolipoprotein A1, g/l 1.1 (0.9-1.3) 1.1 (1.0-1.3) <0.001 1.1 (1.0-1.3) 1.1 (0.9-1.3) <0.001
Apolipoprotein B, g/l 0.9 (0.7-1.1) 0.9 (0.7-1.1) 0.666 0.9 (0.7-1.0) 1.0 (0.8-1.1) <0.001
Apolipoprotein
B/Apolipoprotein A1
0.8 (0.6-1.0) 0.8 (0.6-1.0) <0.001 0.7 (0.6-0.9) 0.9 (0.7-1.1) <0.001
Fasting plasma glucose, mmol/l 5.1 (4.7-5.6) 5.0 (4.7-5.5) 0.204 4.9 (4.6-5.3) 5.4 (5.0-6.1) <0.001
HOMA-IR 2.3 (1.6-3.5) 2.4 (1.6-3.5) 0.091 1.8 (1.3-2.3) 4.2 (3.4-6.2) <0.001
Uric acid, mmol/l 341.0 (289.0-404.0) 256.0 (213.0-310.0) <0.001 286.0 (232.0-347.0) 314.0 (255.0-384.0) <0.001
Hypersensitive C-reactive protein, mg/l 1.0 (1.0-2.0) 1.0 (0.1-2.0) <0.001 1.0 (0.1-2.0) 1.0 (1.0-3.0) <0.001

















Table 2 Multiple linear regression models for predicting homeostatic model assessment
Men Women
Model 1 Model 2 Model 3 Model 1 Model 2 Model 3
Additional R2 β Additional R2 β Additional R2 β Additional R2 β Additional R2 β Additional R2 β
Lipid measures
Ln TC 0.001 0.129* 0.002 0.168* 0.002 0.163† 0.001 0.086 0.004 0.229† 0.001 0.1
Ln TG 0.027 0.26† 0.031 0.239† 0.03 0.268† 0.022 0.223† 0.043 0.286† 0.025 0.237†
Ln LDL-C 0.001 0.045 0 0.006 0.001 0.066 0.001 0.07* 0.002 0.099* 0.001 0.071*
Ln Non-HD
L-C
0.005 0.204† 0.007 0.230† 0.007 0.243† 0.003 0.147† 0.011 0.264† 0.004 0.166†
Ln Apo B 0.003 0.151* 0.004 0.160† 0.004 0.171† 0.006 0.194† 0.014 0.284† 0.006 0.204†
Ln HDL-C 0.009 -0.333† 0.013 -0.354† 0.014 -0.373† 0.005 -0.211† 0.01 -0.306† 0.006 -0.238
Ln Apo A-I 0.006 -0.235† 0.006 -0.237† 0.007 -0.261† 0 -0.01 0 -0.005 0 -0.014
Lipid ratios
Ln TC/HDL-C 0.014 0.339† 0.017 0.355† 0.018 0.383† 0.007 0.229† 0.019 0.370† 0.008 0.257†
Ln TG/ HDL-C 0.029 0.212† 0.033 0.197† 0.033 0.224† 0.023 0.170† 0.045 0.221† 0.026 0.181†
Ln LDL-C/
HDL-C
0.01 0.160† 0.016 0.146† 0.015 0.190† 0.006 0.157† 0.012 0.224† 0.007 0.17†
Ln Non- HDL-
C/HDL-C
0.013 0.227† 0.016 0.239† 0.017 0.257† 0.007 0.163† 0.019 0.256† 0.009 0.182†
Ln Apo
B/apo A-I
0.01 0.213† 0.011 0.221† 0.013 0.237† 0.004 0.136† 0.01 0.204† 0.005 0.145†
Visceral adiposity indicators
Ln LAP 0.017 0.141† 0.021 0.143† 0.015 0.165† 0.016 0.147† 0.033 0.195† 0.017 0.178†
Ln VAI 0.031 0.213† 0.034 0.198† 0.031 0.217† 0.021 0.172† 0.042 0.222† 0.02 0.173†
TyG index 0.091 0.390† 0.089 0.347† 0.095 0.40† 0.078 0.359† 0.107 0.381† 0.08 0.367†
*P <0.05. †P <0.001.
Model 1 was adjusted for age, rural/urban settings, region, education level, smoking status, alcohol use, body mass index, systolic blood pressure, uric acid, and
hs-CRP. Model 2 was adjusted for all the variables in model 1 plus waist circumference.
Model 3 was adjusted for body mass index, rural/urban settings, region, education level, alcohol use, and Framingham Risk Score (low, intermediate, and high).
TC, total cholesterol; TG: triglycerides; LDL-C: low density lipoprotein cholesterol; HDL-C: high density lipoprotein cholesterol; Apo B: apolipoprotein B; Apo A-I:
apolipoprotein A1; LAP: lipid accumulation product; VAI: visceral adiposity index; TyG index: the product of triglycerides and fasting glucose.
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lipid parameters, for both sexes, in terms of their strengths
of association with IR, lipid ratios performed better overall
than any of the individual variables used alone; there was
no indication that apoB/apoA-I was superior to traditional
lipid ratios; the lipid ratio with the strongest association
was TG/HDL-C (top vs bottom OR [95% CI] was 3.04
[2.40-2.85] for men, and 2.70 [2.17-3.36] for women).
For all variables of interest, among both sexes, OR for
IR with quartile 4 versus quartile 1 was highest for TyG
(5.58 for men and 5.18 for women); the effect of VAI,
which was superior to LAP, was comparable to TG/HDL-C.
Results were largely replicated in models 2 and 3.
Areas under the ROC curves derived from lipid ratios
were in general significantly greater than from single lipids
(Table 4). For all lipid ratios, the AUC for the TG/HDL-C
was greatest in both sexes (0.665 in men and 0.664 in
women). For comparison, the AUC for apoB/apoA-I was
0.625 in men and 0.613 in women. For all variables ofinterest, among both genders, TyG presented the greatest
value of AUC (0.709 in men and 0.711 in women); the
AUC for VAI (0.695 in men and 0.682 in women) was
greater than that for TG/HDL-C.
Since WC has a strong effect on IR and was sensitive for
discriminating lipids abnormalities [21], we selected the 3
variables with the greatest AUCs (TG/HDL-C, VAI, and
TyG), which also explained the most variability in HOMA-
IR and had the highest ORs in the fourth quartile, to inves-
tigate whether the relationships between each of the 3
variables and IR differed by WC status (central obese
and non-central obese). After adjusting for BMI, socio-
economic status, alcohol use, and FRS, all the 3 vari-
ables remained significant predictors of IR irrespective
of WC status (Table 5). Moreover, the interactions be-
tween WC levels and each of the 3 variables on IR did
not reach statistical significance, indicating that the associ-
ations of each of the 3 variables with IR did not differ by
WC status.
Table 3 Adjusted odds ratios of insulin resistance among those in the extreme quartiles of each evaluated variable
Men Women
Model 1 Model 2 Model 3 Model 1 Model 2 Model 3
Lipid measures
TC 1.23 (0.99-1.52) 1.30 (1.06-1.61) 1.27 (1.03-1.57) 1.17 (0.96-1.44) 1.36 (1.11-1.66) 1.19 (0.97-1.47)
TG 2.78 (2.20-3.51) 2.86 (2.29-3.57) 2.92 (2.31-3.68) 2.70 (2.17-3.36) 3.36 (2.72-4.14) 2.88 (2.32-3.58)
LDL-C 1.13 (0.92-1.39) 1.09 (0.88-1.34) 1.19 (0.96-1.46) 1.13 (0.92-1.39) 1.17 (0.96-1.43) 1.13 (0.92-1.38)
Non-HDL-C 1.64 (1.31-2.05) 1.74 (1.40-2.16) 1.74 (1.40-2.17) 1.46 (1.18-1.81) 1.80 (1.47-2.21) 1.51 (1.22-1.87)
Apo B 1.55 (1.25-1.92) 1.61 (1.30-1.99) 1.59 (1.28-1.97) 1.69 (1.37-2.10) 2.01 (1.63-2.47) 1.69 (1.36-2.09)
HDL-C 0.52 (0.42-0.65) 0.50 (0.41-0.63) 0.49 (0.39-0.61) 0.66 (0.54-0.81) 0.55 (0.46-0.67) 0.64 (0.52-0.78)
Apo A-I 0.70 (0.57-0.86) 0.70 (0.57-0.86) 0.67 (0.54-0.82) 0.93 (0.77-1.13) 0.92 (0.76-1.11) 0.92 (0.76-1.12)
Lipid ratios
TC/HDL-C 2.14 (1.70-2.68) 2.22 (1.78-2.77) 2.31 (1.84-2.89) 1.87 (1.51-2.32) 2.38 (1.93-2.92) 1.97 (1.59-2.44)
TG/HDL-C 3.04 (2.40-3.85) 3.09 (2.47-3.87) 3.19 (2.53-4.04) 2.70 (2.17-3.36) 3.39 (2.75-4.17) 2.86 (2.30-3.56)
LDL-C/HDL-C 1.57 (1.26-1.95) 1.55 (1.25-1.92) 1.71 (1.38-2.12) 1.57 (1.28-1.93) 1.80 (1.47-2.19) 1.59 (1.29-1.95)
Non- HDL-C/HDL-C 2.14 (1.70-2.68) 2.22 (1.78-2.77) 2.31 (1.84-2.89) 1.87 (1.51-2.32) 2.38 (1.93-2.92) 1.97 (1.59-2.44)
Apo B/apo A-I 1.85 (1.49-2.31) 1.91 (1.54-2.37) 1.96 (1.58-2.43) 1.61 (1.31-1.98) 1.87 (1.53-2.28) 1.63 (1.33-2.01)
Visceral adiposity indicators
LAP 3.02 (2.39-3.81) 3.06 (2.45-3.82) 3.21 (2.52-4.08) 2.31 (1.79-2.98) 3.01 (2.38-3.81) 2.59 (2.07-3.23)
VAI 3.1 (2.35-4.07) 3.16 (2.43-4.18) 3.76 (2.7-5.24) 2.45 (1.98-3.05) 3.12 (2.54-3.82) 2.86 (2.13-3.84)
TyG index 5.58 (4.37-7.14) 5.29 (4.19-6.69) 5.74 (4.49-7.33) 5.18 (4.10-6.54) 5.91 (4.75-7.35) 5.37 (4.25-6.77)
Model 1 was adjusted for age, rural/urban settings, region, education level, smoking status, alcohol use, body mass index, systolic blood pressure, uric acid, and
hs-CRP. Model 2 was adjusted for all the variables in model 1 plus waist circumference.
Model 3 was adjusted for body mass index, rural/urban settings, region, education level, alcohol use, and Framingham Risk Score (low, intermediate, and high).
TC, total cholesterol; TG: triglycerides; LDL-C: low density lipoprotein cholesterol; HDL-C: high density lipoprotein cholesterol; Apo B: apolipoprotein B; Apo A-I:
apolipoprotein A1; LAP: lipid accumulation product; VAI: visceral adiposity index; TyG index: the product of triglycerides and fasting glucose.
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by HOMA2-IR as greater than the 75th percentile, which
was calculated using the HOMA2 calculator updated in
2007 (data not shown).
Discussion
In the present study, we directly compared lipid and apoli-
poprotein measures, lipid ratios, LAP, VAI, and TyG as
predictors of IR. Overall, we observed that lipid ratios were
superior to either pro-atherogenic or anti-atherogenic frac-
tions alone. The apoB/apoA-I performed no better than
any of the traditional lipid ratios. Of the lipid ratios, the
magnitude of the association was greatest for TG/HDL-C.
TyG appears to be most closely associated with IR among
all the variables studied. VAI and TG/HDL-C were equiva-
lent in their relationships with IR. Moreover, ROC curve
analysis confirmed these observations by indicating that
TG/HDL-C was better than apoB/apoA-I in discriminat-
ing IR and TyG was the best discriminator in identifying
IR.
There have been several reports suggest that traditional
lipid ratios have greater predictive power for IR and CVD
risk than each of the single standard lipid measures
[2,22,23]. However, there has been very few study address
the crucial question of whether apoB/apoA-I predicts IRbetter than traditional lipid ratios do. Plasma apoB con-
centration provides a measure of the concentration of all
potentially atherogenic particles (Each very low–density
lipoprotein, intermediate-density lipoprotein, and LDL
particle is covered by 1 apoB molecule), and increased
small dense LDL particles is related with IR and CVD
risk. On the other hand, apoA-I is the main structural pro-
tein of HDL particles. Consequently, apoB/apoA-I has been
recommended as an effective indicator to assess CVD risk
[7]. However, the question of whether apoB/apoA-I should
be introduced into guidelines as a target for therapy in
people with dyslipidemia is a debated issue, as some reports
indicated that apoB/apoA-I were better predictors of CVD
risk compared with traditional lipid ratios [22,23], and other
studies reported that apoB/apoA-I and non-HDL-C/HDL-
C were comparable in terms of predicting CVD risk [8,24].
Accumulating evidence indicates that IR facilitates the
development of CVD. However, data on direct compar-
isons between traditional lipid ratios and apoB/apoA-I
to identify IR is limited. Despite the evidence that apoB/
apoAI ratio is significantly associated with IR [6], we found
apoB/apoA1apoA-I has little to offer over traditional lipid
ratios (TC/HDL-C, LDL-C/HDL-C, and non-HDL-C/
HDL-C) in predicting IR. One possible explanation for this
result may be that 90% of apoB-carrying particles are
Table 4 Areas under the receiver operating characteristic




TC 0.558 (0.539-0.578) 0.566 (0.547-0.584)
TG 0.657 (0.638-0.675) 0.662 (0.645-0.679)
LDL-C 0.538 (0.519-0.558) 0.550 (0.532-0.569)
Non-HDL-C 0.606 (0.587-0.625) 0.602 (0.584-0.619)
Apo B 0.596 (0.577-0.615) 0.608 (0.590-0.627)
HDL-C 0.376 (0.357-0.395) 0.402 (0.384-0.420)
Apo A-I 0.427 (0.408-0.446) 0.471 (0.453-0.490)
Lipid ratios
TC/HDL-C 0.568 (0.549-0.578) 0.576 (0.557-0.584)
TG/HDL-C 0.665 (0.647-0.684) 0.664 (0.647-0.681)
LDL-C/HDL-C 0.611 (0.592-0.630) 0.606 (0.588-0.624)
Non- HDL-C/HDL-C 0.646 (0.627-0.664) 0.632 (0.615-0.650)
Apo B/apo A-I 0.625 (0.606-0.644) 0.613 (0.595-0.631)
Visceral adiposity indicators
LAP 0.671 (0.652-0.689) 0.666 (0.649-0.684)
VAI 0.695 (0.677-0.713) 0.682 (0.665-0.699)
TyG 0.709 (0.692-0.726) 0.711 (0.695-0.728)
TC, total cholesterol; TG: triglycerides; LDL-C: low density lipoprotein cholesterol;
HDL-C: high density lipoprotein cholesterol; Apo B: apolipoprotein B; Apo A-I:
apolipoprotein A1; LAP: lipid accumulation product; VAI: visceral adiposity
index; TyG index: the product of triglycerides and fasting glucose.




TG/HDL WC <90 cm 1 1.43 (1.11
WC ≥90 cm 1.29 (0.84-1.97) 1.86 (1.29
VAI WC <90 cm 1 1.30 (1.02
WC ≥90 cm 1.10 (0.70-1.75) 1.60 (1.11
TyG WC < 90 cm 1 1.65 (1.26
WC ≥90 cm 1.22 (0.77-1.92) 2.41 (1.66
Women
TG/HDL WC <80 cm 1 1.43 (1.07
WC ≥80 cm 1.23 (0.89-1.69) 1.59 (1.18
VAI WC <80 cm 1 1.25 (0.95
WC ≥80 cm 1.13 (0.82-1.55) 1.29 (0.97
TyG WC < 80 cm 1 1.55 (1.15
WC ≥80 cm 1.08 (0.76-1.54) 1.94 (1.43
*P for interaction terms (TG/HDL ×WC status, VAI × WC status, and TyG ×WC status)
TG: triglycerides; WC, waist circumference; HDL-C: high density lipoprotein choleste
fasting glucose.
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dicated that LDL-C has little correlation with IR. More-
over, the OR for TG/HDL-C was greater than that for
apoB/apoA-I. Furthermore, evidence shows that two
simple algorithms to calculate apoB from routine lipids
are effective in estimating measured apoB [25].Taken to-
gether, these results provide little support for replacing
measurement of traditional lipid ratios with measurement
of the apoB/apoA-I ratio as risk prediction tools. This
information is of pragmatic interest, as traditional lipid
ratios can be directly calculated from traditional lipid
measures at no incremental cost.
Although lipoproteins and apolipoproteins were not
measured by the more sophisticated method nuclear mag-
netic resonance spectroscopy, emerging evidence suggested
that the association of coronary artery calcification with
nuclear magnetic resonance-measured lipoproteins was
comparable to that with standard lipids [26]. It has been
reported that the sensitivity and specificity for TG/HDL-C
in identifying IR are virtually identical to those for fasting
insulin concentration [27]. Furthermore, TG/HDL-C
has been shown to have a stronger correlation with IR
when compared with other traditional lipid or lipid ratios
[28,29]. However, correlations between TG/HDL-C and IR
differ according to ethnic origin [30]. Thus, it is possible
that how well TG/HDL-C correlates with IR depends
on the target population. Our study appears to be the first
Chinese population-based study using a large database of
cohort for exploring whether TG/HDL-C is a better cor-
relate of IR compared with other lipid measures. Consist-
ent with other studies [28,29,31], we found TG/HDL-Crding to levels of waist circumference and TG/HDL,
Q3 Q4 P*
-1.84) 1.81 (1.40-2.35) 3.23 (2.47-4.22) 0.779
-2.68) 2.65 (1.90-3.70) 3.73 (2.73-5.11)
-1.67) 1.69 (1.31-2.18) 3.13 (2.40-4.08) 0.943
-2.30) 2.39 (1.73-3.29) 3.35 (2.48-4.53)
-2.17) 2.60 (1.99-3.39) 5.60 (4.24-7.40) 0.408
-3.48) 3.54 (2.51-4.97) 5.95 (4.30-8.21)
-1.90) 1.70 (1.26-2.29) 3.97 (2.89-5.47) 0.793
-2.14) 2.57 (1.93-3.41) 3.82 (2.88-5.08)
-1.65) 1.55 (1.16-2.08) 3.85 (2.79-5.31) 0.864
-1.72) 2.23 (1.71-2.91) 3.15 (2.42-4.11)
-2.09) 2.46 (1.81-3.34) 6.72 (4.83-9.34) 0.634
-2.64) 3.18 (2.38-4.26) 6.09 (4.54-8.18)
were assessed by logistic regression analysis.
rol; VAI: visceral adiposity index; TyG index: the product of triglycerides and
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ters. Given that standard assay for TG and HDL-C are
widely available in clinical practice, and that it is simple to
calculate TG/HDL-C from TG and HDL-C, as well as that
TG/HDL-C is superior to other lipid parameters in predict-
ing IR, it is reasonable to recommend TG/HDL-C as an
effective and convenient indicator of IR.
Since the concurrence of hypertriglyceridemia and low
HDL-C are key metabolic abnormalities in patients with
IR and represent diabetic dyslipidemia, it is expected that
we found a superiority of TG/HDL-C over other lipid mea-
sures in correlating IR. However, it is worth emphasizing
that variations in several parameters (levels of lecithin:
cholesterol acyltransferase, post-heparin hepatic lipase ac-
tivities, post-heparin lipoprotein lipase activities, phospho-
lipid transfer protein) that control the plasma lipoprotein
metabolism are related to an increased degree of insulin
sensitivity among healthy (BMI <30 Kg/m2) high HDL-C
(>60 mg/dL) subjects [32]. Binding and internalization
rates of TG-enriched HDL in these subjects may slow
down [33], inducing a relatively lower level of IR.
Our study is the only one directly comparing the utility
of VAI with different lipid measures in assessing IR risk.
We found that the VAI, which take account of the concen-
trations of TG and HDL-C, as well as adiposity measures
(BMI and WC), and TG/HDL-C have comparable associa-
tions with IR. However, when we used ROC analysis to
determine the ability of these 2 indices to discriminate
between persons with and without IR, we found that
VAI was a better discriminator, indicating that VAI offers
more clinical information than that achieved by using TG/
HDL-C. The better ability of VAI to identify IR individuals
compared with TG/HDL-C is of clinical relevance and
can be possibly explained by the fact that the VAI takes
regional body fat distribution into consideration. VAI is
a good indicator of visceral adiposity [11] and visceral
fat is more metabolically deleterious than subcutaneous
fat [13,34]. According to the overflow hypothesis, the
subcutaneous fat depot appears to act as a protective
metabolic sink, storing dietary fat to limit their deposition
in undesired sites such as liver, heart, skeletal muscle, and
pancreatic β cells [34]. However, for some individuals with
more visceral fat and less subcutaneous fat, available lipids
exceed the subcutaneous adipose tissue’s capacity for buff-
ering and storage, the excess of lipids will be reoriented
toward nonadipose tissues [35]. The ectopic lipid deposits
lead to lipotoxicities, incurring insulin resistance. Hence,
obesity is a remarkably heterogeneous disorder, as evi-
denced by the occurrence of a subset of obese persons
who are insulin sensitive, and a subset of normal-weight
people who are insulin resistant [36]. It is with the hetero-
geneity in mind that measuring an indicator of visceral fat
such as VAI is clinically benefit, as visceral obesity is more
important in modulating IR [9,13]. In the current study,LAP, another indicator of visceral adiposity, does not offer
any clinical benefit as compared with TG/HDL-C. Al-
though explanations for this issue remain to be elucidated,
it is probably related to the fact that LAP does not incorp-
orate anti-atherogenic lipoproteins.
TyG has been recently recommended as a simple and
inexpensive index to evaluate IR [14,15]. Because of the
variability of TG levels according to ethnicity, it is necessary
to assess the utility of TyG in predicting IR in a Chinese
population. The current analysis was initiated to perform
the task. We found that the TyG index was a good discrim-
inator in predicting IR and was a better correlate of IR than
TG/HDL-C, a finding consistent with results from other
studies [14,15]. Moreover, our study extends previous stud-
ies by directly comparing the utility of TyG with visceral
adiposity indicators and other lipid parameters in asses-
sing IR risk. We found that TyG was the best index in
discriminating IR individuals, highlighting that TyG can
serve as a simple index for identifying individuals with
a high risk of IR. The superiority of TyG to any of the
other indices we studied can be possibly explained by the
fact that glucotoxicity and lipotoxicities are key mecha-
nisms in modulation of IR. A recent study indicated that
20/(fasting C-peptide immunoreactivity × fasting glucose)
outperformed HOMA-IR for the assessment of glucose in-
fusion rate measured with the hyperinsulinemic-euglycemic
glucose clamp [37]. Since fasting C-peptide immunoreactiv-
ity was not available in CHNS 2009, we have no way to val-
idate the usefulness of TyG in identifying IR evaluated with
20/(fasting C-peptide immunoreactivity × FPG), and further
research with data of fasting C-peptide immunoreactivity is
warranted.
Our study has several strengths including a well-
established cohort of Chinese population, a vigorous quality
assurance program and the same strict methodology used
to ensure the quality of the data collection over the entire
study period. In addition, we evaluated the performance of
traditional lipid ratios, apo B/apo A-I ratio, VAI, LAP,
and TyG in correlating with IR across the full glycemic
spectrum (from normal glucose tolerance to impaired
glucose tolerance to diabetes). Nevertheless, the present
study has several limitations. The study population is com-
prised of only Chinese adults, thus, extrapolating results
to other racial or ethnic population should be interpreted
cautiously. The cross-sectional design implies that no po-
tential temporal relations can be drawn. Hyperinsulinemic-
euglycemic clamp, the gold standard for evaluating insulin
sensitivity, was not conducted. However, HOMA-IR, a sur-
rogate of IR, has been shown to correlate well with IR
index derived from the euglycemic clamp [38]. The fact
that we have no way to evaluate the associations of TG/
HDL-C and apoB/apoA-I ratio with IR according to LDL
subfraction phenotype is another limitation, as phenotype
B is associated with increased oxidized LDL, glycated
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known as platelet-activating factor acetylhydrolase) ac-
tivity [39] and with increased CVD risk [40].
Conclusions
Apolipoprotein ratios performed no better than any trad-
itional lipid ratio in predicting IR risk. The TG/HDL-C ra-
tio, VAI and TyG index are effective discriminators in
predicting IR. This information is of particular clinical
relevance, as all these 3 indices can be calculated from
common measures such as TG, FPG, and HDL-C, which
are based on standardized measurements and widely avail-
able. The ability of TG/HDL-C to identify IR seems com-
promised by taking account of body fat distribution. The
TyG index is the best marker predicting the risk of IR.
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